Oorja Bio, ORJ-001, ORBIT-IPF, idiopathic pulmonary fibrosis, IPF, pulmonary fibrosis, Phase 2 clinical trial, AEC2 cells, beta-1 integrin, lung tissue repair, antifibrotic therapy

HOUSTON, Texas — October 13, 2026 Oorja Bio, Inc., a clinical-stage biopharmaceutical company developing therapies for fibrotic and cardiopulmonary...